Payment overview · 2025
General Payments
$64.43
3 reported records · 2 companies
Healthcare provider profile · identity verified
Anthony Scola, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ESTERO, FL · NPI 1497946172
Verified facts
What the public records show
CMS Open Payments records show Anthony Scola, M.D. received $64.43 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 78.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.73 | 78.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.70 | 21.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.43 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1155 | 358 |
| Amlodipine Besylate | Amlodipine Besylate | 957 | 296 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 815 | 255 |
| Levothyroxine Sodium | Levothyroxine Sodium | 687 | 192 |
| Losartan Potassium | Losartan Potassium | 619 | 202 |
| Lisinopril | Lisinopril | 493 | 154 |
| Alprazolam | Alprazolam | 369 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 119 |
| Hydrochlorothiazide | Hydrochlorothiazide | 292 | 107 |
| Omeprazole | Omeprazole | 285 | 92 |
| Simvastatin | Simvastatin | 285 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 82 |
| Metformin Hcl Er | Metformin Hcl | 224 | 74 |
| Allopurinol | Allopurinol | 201 | 58 |
| Gabapentin | Gabapentin | 200 | 76 |
| Metformin Hcl | Metformin Hcl | 197 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 65 |
| Trazodone Hcl | Trazodone Hcl | 192 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 101 |
| Famotidine | Famotidine | 181 | 68 |
| Sertraline Hcl | Sertraline Hcl | 178 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 67 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 144 | 44 |
| Valsartan | Valsartan | 144 | 42 |
| Alendronate Sodium | Alendronate Sodium | 143 | 53 |
| Montelukast Sodium | Montelukast Sodium | 141 | 47 |
| Ezetimibe | Ezetimibe | 137 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 132 | 40 |
| Ozempic | Semaglutide | 125 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 43 |
| Eliquis | Apixaban | 120 | 39 |
| Carvedilol | Carvedilol | 119 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 40 |
| Furosemide | Furosemide | 109 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 36 |
| Glimepiride | Glimepiride | 103 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 35 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 90 | 26 |
| Clonazepam | Clonazepam | 89 | 25 |
| Tramadol Hcl | Tramadol Hcl | 89 | 32 |
| Meloxicam | Meloxicam | 88 | 40 |
| Jardiance | Empagliflozin | 87 | 34 |
| Mounjaro | Tirzepatide | 83 | 16 |
| Baclofen | Baclofen | 77 | 28 |
| Bupropion Xl | Bupropion Hcl | 74 | 24 |
| Methylprednisolone | Methylprednisolone | 72 | 65 |
| Spironolactone | Spironolactone | 72 | 27 |
| Atenolol | Atenolol | 71 | 21 |
| Synthroid | Levothyroxine Sodium | 71 | 20 |
| Donepezil Hcl | Donepezil Hcl | 67 | 24 |
| Lorazepam | Lorazepam | 67 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 37 |
| Trulicity | Dulaglutide | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 14 |
| Ramipril | Ramipril | 50 | 13 |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Mirtazapine | Mirtazapine | 49 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 15 |
| Buspirone Hcl | Buspirone Hcl | 47 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 15 |
| Valacyclovir | Valacyclovir Hcl | 45 | 22 |
| Xarelto | Rivaroxaban | 43 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Celecoxib | Celecoxib | 40 | 18 |
| Azithromycin | Azithromycin | 39 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 14 |
| Finasteride | Finasteride | 37 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 14 |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | 11 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 31 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 11 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 19 |
| Prednisone | Prednisone | 30 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | 12 |
| Estradiol | Estradiol | 29 | 14 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 15 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Prolia | Denosumab | 18 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Temazepam | Temazepam | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.43 · 3 records | ABBVIE INC. | Korlym, QULIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error